Journal of the National Cancer Institute
-
J. Natl. Cancer Inst. · Aug 2005
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
Many patients with non-small-cell lung cancer (NSCLC) who achieve radiographic responses to treatment with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib have somatic mutations in the EGFR tyrosine kinase domain. However, little is known about the efficacy of cetuximab, an antibody against the EGFR extracellular domain, in EGFR mutant NSCLC. ⋯ EGFR mutations in NSCLC cells are associated with sensitivity to gefitinib but not to cetuximab.
-
J. Natl. Cancer Inst. · Aug 2005
Editorial CommentGefitinib versus cetuximab in lung cancer: round one.